drugset / Trial / NCT00651638

A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype

NCT00651638

Phase 1 Completed 17 enrolled ArQule, Inc.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

To assess the PK and safety profiles of ARQ 197 in extensive and poor metabolizers, as defined by CYP 2C19 genotype

Timeline

Start
2008-03
Primary completion
2008-05
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tivantinib Small molecule

Indications

No indication recorded.